Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology

Christoph Maack; Michael Lehrke; Johannes Backs; Frank R Heinzel; Jean-Sebastien Hulot; Nikolaus Marx; Walter J Paulus; Patrick Rossignol; Heinrich Taegtmeyer; Johann Bauersachs; Antoni Bayes-Genis; Dirk Brutsaert; Heiko Bugger; Kieran Clarke; Francesco Cosentino; Gilles De Keulenaer; Alessandra Dei Cas; Arantxa González; Martin Huelsmann; Guido Iaccarino; Ida Gjervold Lunde; Alexander R Lyon; Piero Pollesello; Graham Rena; Niels P Riksen; Giuseppe Rosano; Bart Staels; Linda W van Laake; Christoph Wanner; Dimitrios Farmakis; Gerasimos Filippatos; Frank Ruschitzka; Petar Seferovic; Rudolf A de Boer; Stephane Heymans

doi:10.1093/eurheartj/ehy596

Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology

Christoph Maack
, Michael Lehrke
, Johannes Backs
, Frank R Heinzel
, Jean-Sebastien Hulot
, Nikolaus Marx
, Walter J Paulus
, Patrick Rossignol
, Heinrich Taegtmeyer
, Johann Bauersachs
, Antoni Bayes-Genis
, Dirk Brutsaert
, Heiko Bugger
, Kieran Clarke
, Francesco Cosentino
, Gilles De Keulenaer
, Alessandra Dei Cas
, Arantxa González
, Martin Huelsmann
, Guido Iaccarino

Ida Gjervold Lunde, Alexander R Lyon, Piero Pollesello, Graham Rena, Niels P Riksen, Giuseppe Rosano, Bart Staels, Linda W van Laake, Christoph Wanner, Dimitrios Farmakis, Gerasimos Filippatos, Frank Ruschitzka, Petar Seferovic, Rudolf A de Boer, Stephane Heymans

Research output: Contribution to journal › Article › Academic › peer-review

4 Downloads (Pure)

Original language	English
Pages (from-to)	4243-4254
Number of pages	12
Journal	European Heart Journal
Volume	39
Issue number	48
DOIs	https://doi.org/10.1093/eurheartj/ehy596
Publication status	Published - 21 Dec 2018

Access to Document

10.1093/eurheartj/ehy596

ehy596Final published version, 774 KB

Cite this

Maack, C., Lehrke, M., Backs, J., Heinzel, F. R., Hulot, J.-S., Marx, N., Paulus, W. J., Rossignol, P., Taegtmeyer, H., Bauersachs, J., Bayes-Genis, A., Brutsaert, D., Bugger, H., Clarke, K., Cosentino, F., De Keulenaer, G., Dei Cas, A., González, A., Huelsmann, M., ... Heymans, S. (2018). Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. European Heart Journal, 39(48), 4243-4254. https://doi.org/10.1093/eurheartj/ehy596

@article{a593d9684db34377b92424a815264202,

title = "Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology",

author = "Christoph Maack and Michael Lehrke and Johannes Backs and Heinzel, \{Frank R\} and Jean-Sebastien Hulot and Nikolaus Marx and Paulus, \{Walter J\} and Patrick Rossignol and Heinrich Taegtmeyer and Johann Bauersachs and Antoni Bayes-Genis and Dirk Brutsaert and Heiko Bugger and Kieran Clarke and Francesco Cosentino and \{De Keulenaer\}, Gilles and \{Dei Cas\}, Alessandra and Arantxa Gonz{\'a}lez and Martin Huelsmann and Guido Iaccarino and Lunde, \{Ida Gjervold\} and Lyon, \{Alexander R\} and Piero Pollesello and Graham Rena and Riksen, \{Niels P\} and Giuseppe Rosano and Bart Staels and \{van Laake\}, \{Linda W\} and Christoph Wanner and Dimitrios Farmakis and Gerasimos Filippatos and Frank Ruschitzka and Petar Seferovic and \{de Boer\}, \{Rudolf A\} and Stephane Heymans",

note = "Funding Information: received speaker honoraria from Servier, Boehringer Ingelheim, Bayer, Bristol Myers Squibb, Pfizer, Daiichi Sankyo, Novartis and Berlin Chemie. M.L. serves as an advisor to MSD, Boehringer Ingelheim, Novo Nordisk, Amgen and received speaker honoraria from MSD, Boehringer Ingelheim, Novo Nordisk, Amgen, Sanofi, Bayer, Lilly, Astra Zeneca. J.B. serves as an advisor to and received speaker honoraria from Bayer, Servier, Novartis, Boehringer Ingelheim, Bristol Myers Squibb, Pfizer, Daiichi Sankyo; he also received research support from Bayer. N.M. has served as a speaker for Amgen, Bayer, Boehringer Ingelheim, Sanofi-Aventis, MSD, BMS, AstraZeneca, Lilly, NovoNordisk; Bayer; as an advisor to Amgen, Bayer, Boehringer Ingelheim, Sanofi-Aventis, MSD, BMS, AstraZeneca, NovoNordisk, but declines all personal compensation from pharma or device companies. P.R. reports personal fees (consulting) from Novartis, Relypsa, AstraZeneca, Gr{\"u}nenthal, Stealth Peptides, Fresenius, Vifor Fresenius Medical Care Renal Pharma, Vifor and CTMA; lecture fees from Bayer and CVRx; cofounder of CardioRenal. K.C. is a director of T∆S Ltd, a company spun out of the University of Oxford to develop and commercialize products based on the science of ketone bodies in human nutrition. ADC received speaker honoraria from Boehringer Ingelheim, Eli Lilly, Novo Nordisk, DOC generic, MSD, AstraZeneca, Sanofi. A.R.L. serves as an advisor to Novartis, Servier, Stealth Peptides and Bristol Myers Squibb and received speaker honoraria from Novartis, Servier, Boehringer Ingelheim, AMGEN and Pfizer. MH has received speaker honoraria, advisory board fees and/or travel grants from Novartis, Roche Diagnostics, Pfizer, Vifor Pharma, Merck, Servier and BRAHMS. C.W. received honoraria of steering committee meetings and lecturing from Boehringer-Ingelheim and Genzyme-Sanofi. D.F. has received speaker honoraria, advisory board fees and/or travel grants from Novartis, Servier, Boehringer Ingelheim, Pfizer, Daiichi-Sankyo and Menarini. RB: the UMCG, which employs RB has received research grants and/or fees from AstraZeneca, Bristol-Myers Squibb, Novartis, Roche, Trevena and ThermoFisher GmbH; RB is a minority shareholder of scPharmaceuticals, Inc. and received personal fees from Novartis and Servier. All other authors declared no conflict of interest. Funding Information: 11); and the Innovational Research Incentives Scheme program of the Netherlands Organization for Scientific Research (NWO VIDI, grant 917.13.350). N.M. is supported by the DFG (SFB TRR 219M-03, M-05). H.T. is supported by grants from the National Institutes of Health of the US Public Health Service (HL-RO1 061483 and HL-RO1 073162). A.B.G. was supported by grants from the Ministerio de Educaci{\'o}n y Ciencia (SAF2014-59892; SAF2017-84324), Fundaci{\'o} La MARAT{\'O} de TV3 (201502, 201516), CIBER Cardiovascular (CB16/11/00403), and AdvanceCat 2014-2020. H.B. is supported by the DFG (Bu2126/3-1). A.D.C. was supported by {\textquoteleft}FIL{\textquoteright} funds for research from University of Parma. A.G. was supported by grants from the European Union Commission{\textquoteright}s FP7 programme (HOMAGE and FIBROTARGETS) and ERA-CVD Joint Transnational Call 2016 LYMIT-DIS. G.R. acknowledges recent funding from The Cunningham Trust, MRC (MR/K012924/1) and the Diabetes UK RW and JM Collins studentship. S.H. received funding from the European Union Commission{\textquoteright}s Seventh Framework programme (2007-2013) under grant agreement N° 305507 (HOMAGE), N° 602904 (FIBROTARGETS) and N° 602156 (HECATOS). S.H. acknowledges the support from the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation, CVON-ARENA-PRIME, CVON-EARLY HFPEF, and SHE-PREDICTS. This research is co-financed as a PPP-allowance Research and Innovation by the Ministry of Economic Affairs within Top Sector Life sciences \& Health. Funding Information: C.M. is supported by the Deutsche Forschungsgemeinschaft (DFG; SFB 894, TRR-219, and Ma 2528/7-1), the German Federal Ministry of Education and Science (BMBF; 01EO1504) and the Corona foundation. J.B. is supported by the DFG (SFB 1118) and the DZHK (German Centre for Cardiovascular Research) and by the BMBF. M.L. is supported by the DFG (SFB TRR 219M-03). R.B. is supported by the Netherlands Heart Foundation (CVON DOSIS 2014-40, CVON SHE-PREDICTS-HF 2017-21, and CVON RED-CVD 2017-",

year = "2018",

month = dec,

day = "21",

doi = "10.1093/eurheartj/ehy596",

language = "English",

volume = "39",

pages = "4243--4254",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "48",

}

Maack, C, Lehrke, M, Backs, J, Heinzel, FR, Hulot, J-S, Marx, N, Paulus, WJ, Rossignol, P, Taegtmeyer, H, Bauersachs, J, Bayes-Genis, A, Brutsaert, D, Bugger, H, Clarke, K, Cosentino, F, De Keulenaer, G, Dei Cas, A, González, A, Huelsmann, M, Iaccarino, G, Lunde, IG, Lyon, AR, Pollesello, P, Rena, G, Riksen, NP, Rosano, G, Staels, B, van Laake, LW, Wanner, C, Farmakis, D, Filippatos, G, Ruschitzka, F, Seferovic, P, de Boer, RA & Heymans, S 2018, 'Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology', European Heart Journal, vol. 39, no. 48, pp. 4243-4254. https://doi.org/10.1093/eurheartj/ehy596

Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. / Maack, Christoph; Lehrke, Michael; Backs, Johannes et al.
In: European Heart Journal, Vol. 39, No. 48, 21.12.2018, p. 4243-4254.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Heart failure and diabetes

T2 - metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology

AU - Maack, Christoph

AU - Lehrke, Michael

AU - Backs, Johannes

AU - Heinzel, Frank R

AU - Hulot, Jean-Sebastien

AU - Marx, Nikolaus

AU - Paulus, Walter J

AU - Rossignol, Patrick

AU - Taegtmeyer, Heinrich

AU - Bauersachs, Johann

AU - Bayes-Genis, Antoni

AU - Brutsaert, Dirk

AU - Bugger, Heiko

AU - Clarke, Kieran

AU - Cosentino, Francesco

AU - De Keulenaer, Gilles

AU - Dei Cas, Alessandra

AU - González, Arantxa

AU - Huelsmann, Martin

AU - Iaccarino, Guido

AU - Lunde, Ida Gjervold

AU - Lyon, Alexander R

AU - Pollesello, Piero

AU - Rena, Graham

AU - Riksen, Niels P

AU - Rosano, Giuseppe

AU - Staels, Bart

AU - van Laake, Linda W

AU - Wanner, Christoph

AU - Farmakis, Dimitrios

AU - Filippatos, Gerasimos

AU - Ruschitzka, Frank

AU - Seferovic, Petar

AU - de Boer, Rudolf A

AU - Heymans, Stephane

N1 - Funding Information: received speaker honoraria from Servier, Boehringer Ingelheim, Bayer, Bristol Myers Squibb, Pfizer, Daiichi Sankyo, Novartis and Berlin Chemie. M.L. serves as an advisor to MSD, Boehringer Ingelheim, Novo Nordisk, Amgen and received speaker honoraria from MSD, Boehringer Ingelheim, Novo Nordisk, Amgen, Sanofi, Bayer, Lilly, Astra Zeneca. J.B. serves as an advisor to and received speaker honoraria from Bayer, Servier, Novartis, Boehringer Ingelheim, Bristol Myers Squibb, Pfizer, Daiichi Sankyo; he also received research support from Bayer. N.M. has served as a speaker for Amgen, Bayer, Boehringer Ingelheim, Sanofi-Aventis, MSD, BMS, AstraZeneca, Lilly, NovoNordisk; Bayer; as an advisor to Amgen, Bayer, Boehringer Ingelheim, Sanofi-Aventis, MSD, BMS, AstraZeneca, NovoNordisk, but declines all personal compensation from pharma or device companies. P.R. reports personal fees (consulting) from Novartis, Relypsa, AstraZeneca, Grünenthal, Stealth Peptides, Fresenius, Vifor Fresenius Medical Care Renal Pharma, Vifor and CTMA; lecture fees from Bayer and CVRx; cofounder of CardioRenal. K.C. is a director of T∆S Ltd, a company spun out of the University of Oxford to develop and commercialize products based on the science of ketone bodies in human nutrition. ADC received speaker honoraria from Boehringer Ingelheim, Eli Lilly, Novo Nordisk, DOC generic, MSD, AstraZeneca, Sanofi. A.R.L. serves as an advisor to Novartis, Servier, Stealth Peptides and Bristol Myers Squibb and received speaker honoraria from Novartis, Servier, Boehringer Ingelheim, AMGEN and Pfizer. MH has received speaker honoraria, advisory board fees and/or travel grants from Novartis, Roche Diagnostics, Pfizer, Vifor Pharma, Merck, Servier and BRAHMS. C.W. received honoraria of steering committee meetings and lecturing from Boehringer-Ingelheim and Genzyme-Sanofi. D.F. has received speaker honoraria, advisory board fees and/or travel grants from Novartis, Servier, Boehringer Ingelheim, Pfizer, Daiichi-Sankyo and Menarini. RB: the UMCG, which employs RB has received research grants and/or fees from AstraZeneca, Bristol-Myers Squibb, Novartis, Roche, Trevena and ThermoFisher GmbH; RB is a minority shareholder of scPharmaceuticals, Inc. and received personal fees from Novartis and Servier. All other authors declared no conflict of interest. Funding Information: 11); and the Innovational Research Incentives Scheme program of the Netherlands Organization for Scientific Research (NWO VIDI, grant 917.13.350). N.M. is supported by the DFG (SFB TRR 219M-03, M-05). H.T. is supported by grants from the National Institutes of Health of the US Public Health Service (HL-RO1 061483 and HL-RO1 073162). A.B.G. was supported by grants from the Ministerio de Educación y Ciencia (SAF2014-59892; SAF2017-84324), Fundació La MARATÓ de TV3 (201502, 201516), CIBER Cardiovascular (CB16/11/00403), and AdvanceCat 2014-2020. H.B. is supported by the DFG (Bu2126/3-1). A.D.C. was supported by ‘FIL’ funds for research from University of Parma. A.G. was supported by grants from the European Union Commission’s FP7 programme (HOMAGE and FIBROTARGETS) and ERA-CVD Joint Transnational Call 2016 LYMIT-DIS. G.R. acknowledges recent funding from The Cunningham Trust, MRC (MR/K012924/1) and the Diabetes UK RW and JM Collins studentship. S.H. received funding from the European Union Commission’s Seventh Framework programme (2007-2013) under grant agreement N° 305507 (HOMAGE), N° 602904 (FIBROTARGETS) and N° 602156 (HECATOS). S.H. acknowledges the support from the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation, CVON-ARENA-PRIME, CVON-EARLY HFPEF, and SHE-PREDICTS. This research is co-financed as a PPP-allowance Research and Innovation by the Ministry of Economic Affairs within Top Sector Life sciences & Health. Funding Information: C.M. is supported by the Deutsche Forschungsgemeinschaft (DFG; SFB 894, TRR-219, and Ma 2528/7-1), the German Federal Ministry of Education and Science (BMBF; 01EO1504) and the Corona foundation. J.B. is supported by the DFG (SFB 1118) and the DZHK (German Centre for Cardiovascular Research) and by the BMBF. M.L. is supported by the DFG (SFB TRR 219M-03). R.B. is supported by the Netherlands Heart Foundation (CVON DOSIS 2014-40, CVON SHE-PREDICTS-HF 2017-21, and CVON RED-CVD 2017-

PY - 2018/12/21

Y1 - 2018/12/21

U2 - 10.1093/eurheartj/ehy596

DO - 10.1093/eurheartj/ehy596

M3 - Article

C2 - 30295797

SN - 0195-668X

VL - 39

SP - 4243

EP - 4254

JO - European Heart Journal

JF - European Heart Journal

IS - 48

ER -